Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) COO Margaret A. Horn sold 50,000 shares of the firm’s stock in a transaction on Friday, October 11th. The shares were sold at an average price of $50.34, for a total value of $2,517,000.00. Following the sale, the chief operating officer now directly owns 132,320 shares of the company’s stock, valued at $6,660,988.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Revolution Medicines Price Performance
RVMD opened at $50.42 on Thursday. The firm has a market cap of $8.42 billion, a price-to-earnings ratio of -13.85 and a beta of 1.43. Revolution Medicines, Inc. has a 1 year low of $15.44 and a 1 year high of $51.00. The stock’s 50 day simple moving average is $44.51 and its 200 day simple moving average is $41.09.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04). The firm had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $0.81 million. The business’s revenue was down 73.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.92) EPS. As a group, sell-side analysts anticipate that Revolution Medicines, Inc. will post -3.35 EPS for the current year.
Analyst Ratings Changes
Check Out Our Latest Report on Revolution Medicines
Institutional Investors Weigh In On Revolution Medicines
A number of large investors have recently made changes to their positions in RVMD. Susquehanna Fundamental Investments LLC purchased a new position in shares of Revolution Medicines in the 1st quarter valued at approximately $6,656,000. Mass General Brigham Inc purchased a new position in Revolution Medicines during the first quarter valued at $10,900,000. Vanguard Group Inc. raised its stake in Revolution Medicines by 0.8% during the first quarter. Vanguard Group Inc. now owns 14,757,112 shares of the company’s stock valued at $475,622,000 after buying an additional 122,721 shares during the last quarter. Seven Eight Capital LP purchased a new position in Revolution Medicines during the first quarter valued at $2,208,000. Finally, Price T Rowe Associates Inc. MD raised its stake in Revolution Medicines by 3.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,814,310 shares of the company’s stock valued at $155,166,000 after buying an additional 177,957 shares during the last quarter. 94.34% of the stock is currently owned by institutional investors.
About Revolution Medicines
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Featured Stories
- Five stocks we like better than Revolution Medicines
- Bank Stocks – Best Bank Stocks to Invest In
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Overbought Stocks Explained: Should You Trade Them?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Why Are Stock Sectors Important to Successful Investing?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.